Portal de Periódicos da CAPES

DOES EARLY CYSTECTOMY IMPROVE THE SURVIVAL OF PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS?

2001; Lippincott Williams & Wilkins; Volume: 166; Issue: 4 Linguagem: Inglês

10.1016/s0022-5347(05)65756-4

1527-3792

Harry W. Herr, Pramod C. Sogani,

Urinary Bladder and Prostate Research

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Oct 2001DOES EARLY CYSTECTOMY IMPROVE THE SURVIVAL OF PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS? HARRY W. HERR and PRAMOD C. SOGANI HARRY W. HERRHARRY W. HERR and PRAMOD C. SOGANIPRAMOD C. SOGANI View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65756-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compared survival after early versus delayed cystectomy in patients with high risk superficial bladder tumors. Materials and Methods: Of 307 patients with high risk superficial bladder tumors who were treated initially with transurethral resection and bacillus Calmette-Guerin (BCG) therapy 90 (29%) underwent cystectomy for recurrent tumor during a followup of 15 to 20 years. Disease specific survival distribution of these 90 patients was determined relative to the indications for and time of cystectomy. Results: Of the 90 patients who underwent cystectomy 44 (49%) survived a median of 96 months. Of 35 patients with recurrent superficial bladder tumors 92% and 56% survived who underwent cystectomy less than 2 years after initial BCG therapy and after 2 years of followup, respectively. Of 55 patients with recurrent muscle invasive bladder disease 41% and 18% survived when cystectomy was performed within and after 2 years, respectively. Multivariate analysis showed that survival was improved in patients who underwent earlier rather than delayed cystectomy for nonmuscle invasive tumor relapse. Conclusions: Earlier cystectomy improves the long-term survival of patients with high risk superficial bladder tumors in whom BCG therapy fails. References 1 : Intravesical BCG therapy prevents tumor progression and death from superficial bladder cancer: ten-year followup of a prospective randomized trial. J Clin Oncol1995; 13: 1404. Google Scholar 2 : The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol1997; 158: 62. Link, Google Scholar 3 : Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). American Urological Association. J Urol1999; 162: 1697. Abstract, Google Scholar 4 : Indications for early cystectomy. Semin Urol Oncol2000; 18: 289. Medline, Google Scholar 5 : Superficial bladder cancer treated with BCG: a multivariate analysis of factors affecting tumor progression. J Urol1989; 141: 22. Abstract, Google Scholar 6 : Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol1994; 151: 31. Link, Google Scholar 7 : Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer1995; 76: 833. Crossref, Medline, Google Scholar 8 : Overexpression of p53 protein in high-risk population of patients with superficial bladder cancer before and after BCG therapy: correlation to clinical outcome. J Clin Oncol1996; 14: 2646. Google Scholar From the Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byO'Donnell M (2022) Navigating the Treacherous Waters of Bacillus Calmette-Guérin FailureJournal of Urology, VOL. 209, NO. 1, (23-24), Online publication date: 1-Jan-2023.McElree I, Packiam V, Steinberg R, Mott S, Gellhaus P, Nepple K and O'Donnell M (2022) Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non–Muscle-Invasive Bladder CancerJournal of Urology, VOL. 208, NO. 5, (969-977), Online publication date: 1-Nov-2022.Steinberg R, Thomas L, Brooks N, Mott S, Vitale A, Crump T, Rao M, Daniels M, Wang J, Nagaraju S, DeWolf W, Lamm D, Kates M, Hyndman M, Kamat A, Bivalacqua T, Nepple K and O'Donnell M (2019) Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 203, NO. 5, (902-909), Online publication date: 1-May-2020.Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B, Pruthi R, Quale D, Ritch C, Seigne J, Skinner E, Smith N and McKiernan J (2016) Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, VOL. 196, NO. 4, (1021-1029), Online publication date: 1-Oct-2016.Mamtani R, Yang Y, Scott F, Lewis J and Boursi B (2016) Association of Itraconazole, a Hedgehog Inhibitor, and Bladder CancerJournal of Urology, VOL. 196, NO. 2, (343-348), Online publication date: 1-Aug-2016.Dinney C, Fisher M, Navai N, O'Donnell M, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman H, Kamat A, Gonzales M, Kincaid M, Ainslie N, Maneval D, Wszolek M and Benedict W (2013) Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 190, NO. 3, (850-856), Online publication date: 1-Sep-2013.Barlow L, McKiernan J and Benson M (2012) Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin TherapyJournal of Urology, VOL. 189, NO. 3, (834-839), Online publication date: 1-Mar-2013.Kamat A, Dickstein R, Messetti F, Anderson R, Pretzsch S, Gonzalez G, Katz R, Khanna A, Zaidi T, Wu X, Grossman H and Dinney C (2012) Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective TrialJournal of Urology, VOL. 187, NO. 3, (862-867), Online publication date: 1-Mar-2012.Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A (2011) A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer GroupJournal of Urology, VOL. 186, NO. 6, (2158-2167), Online publication date: 1-Dec-2011.Chade D, Shariat S, Adamy A, Bochner B, Donat S, Herr H and Dalbagni G (2010) Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In SituJournal of Urology, VOL. 184, NO. 2, (464-469), Online publication date: 1-Aug-2010.Chade D, Shariat S, Godoy G, Savage C, Cronin A, Bochner B, Donat S, Herr H and Dalbagni G (2010) Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary SeriesJournal of Urology, VOL. 184, NO. 1, (74-80), Online publication date: 1-Jul-2010.Tilki D, Reich O, Svatek R, Karakiewicz P, Kassouf W, Novara G, Ficarra V, Chade D, Fritsche H, Gerwens N, Izawa J, Lerner S, Schoenberg M, Stief C, Skinner E, Lotan Y, Sagalowsky A and Shariat S (2010) Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical Cystectomy: An International Study of 243 PatientsJournal of Urology, VOL. 183, NO. 5, (1757-1763), Online publication date: 1-May-2010.Ghoneim M, Abdel-Latif M, El-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A and El-Baz M (2008) Radical Cystectomy for Carcinoma of the Bladder: 2,720 Consecutive Cases 5 Years LaterJournal of Urology, VOL. 180, NO. 1, (121-127), Online publication date: 1-Jul-2008.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.Raj G, Herr H, Serio A, Donat S, Bochner B, Vickers A and Dalbagni G (2018) Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder CancerJournal of Urology, VOL. 177, NO. 4, (1283-1286), Online publication date: 1-Apr-2007.Herr H, Donat S and Dalbagni G (2018) Can Restaging Transurethral Resection of T1 Bladder Cancer Select Patients for Immediate Cystectomy?Journal of Urology, VOL. 177, NO. 1, (75-79), Online publication date: 1-Jan-2007.Mahmud S, Fong B, Fahmy N, Tanguay S and Aprikian A (2018) Effect of Preoperative Delay on Survival in Patients With Bladder Cancer Undergoing Cystectomy in Quebec: A Population Based StudyJournal of Urology, VOL. 175, NO. 1, (78-83), Online publication date: 1-Jan-2006.LIEDBERG F, ANDERSON H and MÅNSSON W (2018) TREATMENT DELAY AND PROGNOSIS IN INVASIVE BLADDER CANCERJournal of Urology, VOL. 174, NO. 5, (1777-1781), Online publication date: 1-Nov-2005.THALMANN G, MARKWALDER R, SHAHIN O, BURKHARD F, HOCHREITER W and STUDER U (2018) PRIMARY T1G3 BLADDER CANCER: ORGAN PRESERVING APPROACH OR IMMEDIATE CYSTECTOMY?Journal of Urology, VOL. 172, NO. 1, (70-75), Online publication date: 1-Jul-2004.CHANG S, HASSAN J, COOKSON M, WELLS N and SMITH J (2018) Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological StageJournal of Urology, VOL. 170, NO. 4 Part 1, (1085-1087), Online publication date: 1-Oct-2003.PEYROMAURE M, GUERIN F, AMSELLEM-OUAZANA D, SAIGHI D, DEBRE B and ZERBIB M (2018) Intravesical Bacillus Calmette-Guerin Therapy for Stage T1 Grade 3 Transitional Cell Carcinoma of the Bladder: Recurrence, Progression and Survival in a Study of 57 PatientsJournal of Urology, VOL. 169, NO. 6, (2110-2112), Online publication date: 1-Jun-2003.HERR H and DALBAGNI G (2018) Defining Bacillus Calmette-Guerin Refractory Superficial Bladder TumorsJournal of Urology, VOL. 169, NO. 5, (1706-1708), Online publication date: 1-May-2003.SÁNCHEZ-ORTIZ R, HUANG W, MICK R, VAN ARSDALEN K, WEIN A and MALKOWICZ S (2018) An Interval Longer than 12 Weeks Between the Diagnosis of Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder CarcinomaJournal of Urology, VOL. 169, NO. 1, (110-115), Online publication date: 1-Jan-2003.SHAHIN O, THALMANN G, RENTSCH C, MAZZUCCHELLI L and STUDER U (2018) A Retrospective Analysis of 153 Patients Treated With or Without Intravesical Bacillus Calmette-Guerin for Primary Stage T1 Grade 3 Bladder Cancer: Recurrence, Progression and SurvivalJournal of Urology, VOL. 169, NO. 1, (96-100), Online publication date: 1-Jan-2003. Volume 166Issue 4October 2001Page: 1296-1299 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsbladder neoplasmsriskcystectomybladderMycobacterium bovisMetricsAuthor Information HARRY W. HERR More articles by this author PRAMOD C. SOGANI More articles by this author Expand All Advertisement PDF downloadLoading ...